Neovii pharmaceuticals AG and Mundipharma have entered into an agreement giving Mundipharma the rights to develop and distribute its polyclonal antibody immunosuppressant Grafalon®, in China and Japan from end October.
SINGAPORE, July 5, 2018 /PRNewswire/ -- Neovii Pharmaceuticals AG of Rapperswil, Switzerland and Mundipharma have entered into an agreement giving Mundipharma the rights to develop and distribute its polyclonal antibody immunosuppressant Grafalon®, in China and Japan from end October.
Logo - http://photos.prnasia.com/prnh/20150302/8521501264LOGO
Grafalon® is indicated in solid organ transplant for prevention and treatment of acute rejection, graft-vs-host disease (GvHD) in stem cell transplant (SCT) and in the treatment of aplastic anemia. Grafalon® is the recognised standard of care in leading transplant centers.
Under its license, Mundipharma intends to strengthen the distribution and support of Grafalon® in these key markets to advance the clinical development for the prevention of chronic GvHD in SCT.
Grafalon® is currently approved for prevention of rejection and the treatment of acute steroid resistant rejection in solid organ transplant in China.
Grafalon®, has been used for over 30 years to treat patients, and is currently available in over 50 countries worldwide. Neovii is a global leader in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology/oncology.
Juergen Pohle, Neovii CEO commented, “We are very enthusiastic to work with Mundipharma as a partner to develop Grafalon® in China further by developing its indication for use in stem cell transplantation and further solidifying the position of Grafalon® as a leading treatment for solid organ transplant patients in China.”
Mundipharma CEO, Raman Singh, said, “We are excited to establish a partnership with Neovii that will have an positive impact on patients in China and Japan, who will have access to the leading technology for prevention of GvHD.
“We view Grafalon® as a strategic complement to our existing haemotology and oncology franchise,” he added. “SCT continues to be the only curative therapy for many patients with leukemia, lymphoma, and Grafalon® has the potential to help them avoid the debilitating and potentially fatal effects of GvHD.”
(R): GRAFALON is a registered trademark of Neovii.
About Grafalon®
Grafalon® is a rabbit anti-human T-lymphocyte immunoglobulin (ATLG), used as part of immunosuppressive regimens for the prevention of graft versus host disease in stem cell transplantation, prevention and treatment of rejection in solid organ transplantation or as immunosuppressive in the treatment of aplastic anemia (in accordance with country-specific approved indications). With more than 200,000 treated patients to date in more than 50 countries, Grafalon® enjoys worldwide recognition among solid organ and stem cell transplant teams and has transformed the way transplant teams manage the care of their patients around the world.
About Neovii
Neovii is an independent, dynamic, rapidly-growing and global biopharmaceutical company with a patient-focused mission to develop and market novel life-transforming therapies.
Neovii has been dedicated for over three decades to improving the outcomes in transplantation medicine and the treatment options for hemato-oncological as well as immune disorders. Neovii Pharmaceuticals AG’s global headquarters is located in Rapperswil, Switzerland and has a branch office in Massachusetts, USA. Its biotechnology manufacturing facility is in Graefelfing, Germany. Neovii’s products are available in over 50 countries worldwide.
About Mundipharma
Mundipharma is a network of independent associated companies which are privately owned entities covering pharmaceutical markets in Asia-Pacific, Latin America, the Middle East and Africa. The headquarters for these territories is in Singapore. Mundipharma is a prime example of an organization that consistently delivers high-quality medicines while standing by the values it represents. Its mission is to alleviate the suffering of patients and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.
For more information please visit: www.neovii.com and www.mundipharma.com.sg
SOURCE Mundipharma
